钆塞酸增强MRI上肝转移瘤的肝胆期强化:频率与模式评估
研究评估了80例钆塞酸增强MRI中肝转移瘤的肝胆期强化频率与模式,病灶相对肌肉强化超过20%即视为强化。77%(54/70)直径>1cm的 dominant 病灶出现强化,可见于10种原发恶性肿瘤;PDAC转移瘤强化程度低于CRC和NET,且三种原发肿瘤的强化模式分布不同。
要点
- 直径>1cm的肝转移瘤中77%(54/70)在肝胆期表现为相对肌肉>20%的强化。
- 肝转移瘤肝胆期强化分三型:周边型、中央型(靶型)、弥漫不均匀型。
- PDAC转移瘤以周边型为主(73%),CRC以弥漫不均匀型为主(32%),NET以中央型为主(89%)。
关键影像表现/征象
- 病灶肝胆期强化定义为相对于肌肉的强化超过20%。
- 优势转移灶中77%(54/70)直径>1cm者显示肝胆期强化。
- 肝胆期强化见于10种不同原发恶性肿瘤的肝转移瘤,包括CRC、PDAC和NET。
- 识别出三种强化模式:周边型、中央型(靶型)、弥漫不均匀型。
诊断标准与关键数值
- 病灶肝胆期强化判定标准:相对肌肉的强化超过20%。
- PDAC转移瘤肝胆期强化程度为26%,低于CRC的44%(padj=0.04)和NET的51%(padj=0.01)。
- PDAC周边型比例最高为73%(padj<0.001),CRC弥漫不均匀型比例最高为32%(padj<0.01),NET中央型比例最高为89%(padj<0.001)。
临床应用与阅片要点
- 阅片时应注意肝转移瘤在肝胆期可表现为轻度强化,勿因强化不明显而排除转移瘤。
- 根据原发肿瘤类型留意强化模式:PDAC多周边型、CRC多弥漫不均匀型、NET多中央型。
- 作者认为HBP强化与OATP1B3表达及预后的关系需针对每种恶性肿瘤进一步专门探索。
局限性
- 原文结论指出HBP强化与OATP1B3表达及预后的相关性有待进一步研究。
- 原文要点指出HBP强化、强化模式、OATP1B3表达与预后之间的关系需针对每种恶性肿瘤进一步专门探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess for and characterize patterns of hepatobiliary phase (HBP) enhancement in hepatic metastases of various malignancies on gadoxetic acid-enhanced MRI.
METHODS: Eighty gadoxetic acid-enhanced MRI studies performed between July 2012 and November 2019 in patients with hepatic metastases from 13 different primary malignancies were assessed. Most (n = 60) were from colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or neuroendocrine tumor (NET) primaries. Two radiologists quantitatively evaluated the dominant lesion on each MRI. A lesion was considered enhancing when HBP enhancement relative to muscle exceeded 20%. Lesions were classified by pattern of enhancement. Quantitative enhancement metrics and patterns of enhancement were compared between CRC, PDAC, and NET using non-parametric statistical tests.
RESULTS: Most dominant metastatic lesions > 1 cm (77%, 54/70) demonstrated HBP enhancement. HBP enhancement was identified in hepatic metastases from 10 different primary malignancies, including CRC, PDAC, and NET. PDAC metastases demonstrated a lower degree of HBP enhancement (26%) than CRC (44%, padj = 0.04) and NET (51%, padj = 0.01) metastases. Three discrete enhancement patterns were identified: peripheral, central (target), and diffuse heterogeneous. Patterns of HBP enhancement varied between CRC, PDAC, and NET, with secondary analysis demonstrating that PDAC had the highest proportion of peripheral pattern (73%, padj < 0.001), CRC the highest proportion of diffuse heterogeneous pattern (32%, padj < 0.01), and NET the highest proportion of central pattern (89%, padj < 0.001).
CONCLUSION: Liver metastases from several primary malignancies, including PDAC, demonstrate mild HBP enhancement in variable patterns. Correlation with OATP1B3 expression and prognosis is required.
KEY POINTS: • Hepatobiliary phase (HBP) enhancement was identified in 77% of hepatic metastases in several different primary malignancies. • Discrete patterns of HBP enhancement exist (peripheral, central, diffuse heterogeneous) and varied between CRC, PDAC, and NET. CRC and PDAC metastases demonstrated mostly non-central patterns (diffuse and peripheral), and NET mostly a central pattern. • Relationship between HBP enhancement, enhancement pattern, OATP1B3 expression, and prognosis requires further dedicated exploration for each malignancy.
引用
- Bhayana R, Baliyan V, Kordbacheh H, et al. Hepatobiliary phase enhancement of liver metastases on gadoxetic acid MRI: assessment of frequency and patterns. Eur Radiol. 2020. PMID: 32886204. doi:10.1007/s00330-020-07228-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。